- Home
- BCYC vs CYRX Comparison
BCYC vs CYRX Comparison
Compare BCYC & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCYC | CYRX |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 472.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCYC | CYRX |
|---|---|---|
| Price | $6.83 | $9.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $18.73 | $12.83 |
| AVG Volume (30 Days) | 244.7K | ★ 489.3K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | $28,339,000.00 | ★ $243,795,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.26 |
| P/E Ratio | ★ N/A | $7.63 |
| Revenue Growth | N/A | ★ 41.27 |
| 52 Week Low | $6.03 | $4.58 |
| 52 Week High | $15.47 | $11.44 |
Technical Indicators
Market Signals| Indicator | BCYC | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 51.41 |
| Support Level | $6.73 | $9.32 |
| Resistance Level | $7.28 | $9.95 |
| Average True Range (ATR) | 0.33 | 0.37 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 11.96 | 37.30 |
Price Performance
Historical ComparisonAbout BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.